Novocure presents 2026 corporate update and clinical progress
The presentation highlights positive phase 3 data in glioblastoma, lung cancer, and pancreatic cancer, plus upcoming launches and trial milestones.
See the latest news and media coverage for Novocure. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global oncology company
novocure.comLast updated
In short: Novocure received FDA approval for Optune Pax in pancreatic cancer and reported record Q2 2026 revenues of $184 million.
The presentation highlights positive phase 3 data in glioblastoma, lung cancer, and pancreatic cancer, plus upcoming launches and trial milestones.
Net revenues reached $184 million, driven by 18% active patient growth, and CE Mark for Optune Pax in locally advanced pancreatic cancer.
The company will host a conference call at 8 a.m. EDT on July 23 to discuss results.
The CE Mark is based on Phase 3 PANOVA-3 trial showing improved overall survival and delayed pain progression.
Oncology company Novocure said on Tuesday a cybersecurity incident involving unauthorized access to...
Jersey-based NovoCure Ltd. generates its revenues primarily through the marketing of the tumor treating fields therapy Optune for the treatment of certain brain and breast cancers. In the...
Real-time stock price of NovoCure with live chart & price development News & analyses Place it for free in your onvista demo portfolio and observe it long-term!
NovoCure (NVCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the...
Track Novocure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.